According to the analysis result, there exist obvious differences [random effects HR, 0.70; 95% (CI), 0.59–0.81; P<0.01] reinforcing the notion that CRP leads to better survival outcomes in oligometastatic prostate cancer patients. The gene discussed is CRP; the disease is Familial prostate cancer.